Pharmacokinetics and pharmacodynamics in antibiotic dose optimization

被引:40
|
作者
Sy, Sherwin K. B. [1 ,2 ]
Zhuang, Luning [1 ,3 ]
Derendorf, Hartmut [1 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
[2] Univ Estadual Maringa, Postgrad Program Biostat, Maringa, Parana, Brazil
[3] US FDA, Div Pharmacometr, Off Clin Pharmacol, Ctr Drug Evaluat & Res, Silver Spring, MD USA
关键词
antibiotics; in vitro models; PK-PD modeling; translational research; CRITICALLY-ILL PATIENTS; COMMUNITY-ACQUIRED PNEUMONIA; INFECTIOUS-DISEASES-SOCIETY; PARA-AMINOSALICYLIC ACID; MUTANT SELECTION WINDOW; STAGE RENAL-DISEASE; PSEUDOMONAS-AERUGINOSA; IN-VITRO; BETA-LACTAMASE; POPULATION PHARMACOKINETICS;
D O I
10.1517/17425255.2016.1123250
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Identifying the optimized dosing regimen and algorithm is critical in the development of antibiotics. Suboptimal regimens and inappropriate choice of drug give rise to drug-resistant bacteria which have limited the therapeutic utility of many commercially available antimicrobial agents. Strategies to optimize therapy of antimicrobial candidates to speed up the development process are urgently needed.Areas covered: We examined pharmacokinetics and pharmacodynamics of antimicrobial agents with modeling and simulation approaches. The approach that is based on minimum inhibitory concentration to evaluate antimicrobial dosing strategy is widely utilized in drug development. The modeling approach utilizing information from time-kill kinetic studies is a tool that can provide more information on the time-course of bacterial response to a particular dosing regimen. Animal studies of dosing regimens that mimic human pharmacokinetics are another option to evaluate antimicrobial efficacy. Empirical, semi-mechanistic and mechanistic models of bacterial dynamics and development of drug resistance in response to drug therapy are discussed.Expert opinion: Both theories and applications of these approaches provide an overall understanding of how the tools can streamline drug development process and help make crucial decisions. Many opportunities and potentials are presented to incorporate more rigorous integration of PK-PD modeling approaches even at preclinical stage to extrapolate to clinical settings, thus enabling successful trials and optimizing dosing strategies in relevant populations where the drug is mostly used.
引用
收藏
页码:93 / 114
页数:22
相关论文
共 50 条
  • [1] Pharmacokinetics and pharmacodynamics of antibiotic therapy
    Beck, S.
    Wicha, S. G.
    Kloft, C.
    Kees, M. G.
    [J]. ANAESTHESIST, 2014, 63 (10): : 775 - 782
  • [2] Pharmacokinetics and pharmacodynamics in HAART and antibiotic therapy
    Boffito, Marta
    [J]. NEW MICROBIOLOGICA, 2007, 30 (03): : 346 - 349
  • [3] Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics
    Papachristos, Apostolos
    Patel, Jai
    Vasileiou, Maria
    Patrinos, George P.
    [J]. CANCERS, 2023, 15 (12)
  • [4] Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy
    Eric Wenzler
    David Butler
    Xing Tan
    Takayuki Katsube
    Toshihiro Wajima
    [J]. Clinical Pharmacokinetics, 2022, 61 : 539 - 552
  • [5] Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy
    Wenzler, Eric
    Butler, David
    Tan, Xing
    Katsube, Takayuki
    Wajima, Toshihiro
    [J]. CLINICAL PHARMACOKINETICS, 2022, 61 (04) : 539 - 552
  • [6] Antibiotic pharmacokinetics/pharmacodynamics: where are we heading?
    Li, Jian
    Roberts, Jason
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 58 (02)
  • [7] β-Lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review
    Sinnollareddy, Mahipal G.
    Roberts, Michael S.
    Lipman, Jeffrey
    Roberts, Jason A.
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2012, 39 (06) : 489 - 496
  • [8] Correction to: Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy
    Eric Wenzler
    David Butler
    Xing Tan
    Takayuki Katsube
    Toshihiro Wajima
    [J]. Clinical Pharmacokinetics, 2022, 61 : 1069 - 1069
  • [9] Pharmacokinetics and pharmacodynamics of intravenous delafloxacin in healthy subjects: model-based dose optimization
    Lv, Jiong-Xian
    Huang, Yi-Huan
    Kafauit, Farah
    Wang, Yuan-Hui
    Su, Chang
    Ma, Jun-Heng
    Xu, Yan
    Huang, Chao-Chao
    Zhang, Qing
    Su, Yu-Wen
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (07)
  • [10] The application of pharmacodynamics in the optimization of antibiotic therapy
    Chung, E
    Amsden, GT
    Nafziger, AN
    Bertino, JS
    [J]. FORMULARY, 2003, 38 (05) : 294 - +